Reported by WuXi AppTec Content Team

On December 11th, Angitia announced the completion of a $120 million Series C funding round led by Bain Capital Life Sciences. The participants in this round of investment include new investor Janus Henderson and existing shareholders Aobo Capital, Sanzheng Health Investment, Yonghua Investment, Junlian Capital, and Lichen Investment. According to the press release, the proceeds from Series C financing will be used to support Anjisheng's innovative drug pipeline, dedicated to developing differentiated and innovative treatment plans for critical bone, joint, and muscle diseases.Anjisheng Biotechnology is an innovative drug research and development company specializing in the field of severe diseases of bones, joints, and muscles. Currently, three biopolymer candidate drugs are in the clinical research stage, aimed at treating osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Among them, the company is advancing the global clinical development of AGA2118 and AGA2115 for the treatment of osteoporosis and osteogenesis imperfecta (OI). These two bispecific antibodies can specifically bind to osteopontin and DKK1, representing a new generation of dual effect therapies for bone diseases that can simultaneously increase bone formation and reduce bone resorption. Anjisheng expects that these two bispecific drugs will help promote stronger and more orderly bone development in patients. Currently, Anjisheng is recruiting postmenopausal women with osteoporosis to participate in the Phase 2 clinical trial of AGA2118, which is currently in the Phase 1 clinical trial stage.

Meanwhile, Anjisheng is developing a biologic agent AGA111 to promote spinal fusion in patients with degenerative disc disease. A phase 3 clinical trial exploring the application of this product in patients undergoing lumbar interbody fusion is currently underway.

Dr. Ke Huazhu, CEO of Anjisheng, said, "The unremitting efforts of the Anjisheng team, the smooth progress of the clinical pipeline, and the high-quality preliminary clinical results are the solid foundation for this round of financing to receive extensive support from well-known professional investment institutions. We sincerely thank new and old investors for their support in developing innovative therapies for musculoskeletal related diseases. We look forward to efficiently promoting the clinical development of drug pipelines for patients and bringing greater social value